Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Article in Journal for ImmunoTherapy of Cancer (June 2018)
The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.
Article in Journal for ImmunoTherapy of Cancer (June 2018)
Article in Journal of Translational Medicine (November 2015)